Cancer of unknown primary origin diagnostic study of choice
|
Cancer of unknown primary origin Microchapters |
|
Differentiating Cancer of Unknown Primary Origin from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cancer of unknown primary origin diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Cancer of unknown primary origin diagnostic study of choice |
|
FDA on Cancer of unknown primary origin diagnostic study of choice |
|
CDC on Cancer of unknown primary origin diagnostic study of choice |
|
Cancer of unknown primary origin diagnostic study of choice in the news |
|
Blogs on Cancer of unknown primary origin diagnostic study of choice |
|
Risk calculators and risk factors for Cancer of unknown primary origin diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: ; Roukoz A. Karam, M.D.[3]
Overview
The diagnosis of cancer of unknown primary origin is made when the following diagnostic criteria are met: tissue biopsy indicating malignancy and all known primary origins of cancer are ruled out.
Diagnostic Study of Choice
- The diagnosis of cancer of unknown primary origin is made when the following diagnostic criteria are met: tissue biopsy indicating malignancy and all known primary origins of cancer are ruled out.
- The search of the primary tumor's anatomical location has proven to be very challenging and costly; nevertheless, it is pursued with focus on the types of tumors that might benefit from efficient and targeted treatment.[1][2]
- The initial approach may vary on a case-by-case basis; however, the diagnosis is made after histopathological and clinical testing:[3]
- The histopathological examination of the tissue includes microscopic evaluation followed by immunohistochemical analysis.
- Clinical diagnostic tests must be exhausted in order to aid in identifying the primary origin and this includes:[4]
- Detailed medical history and full physical exam
- Complete blood count
- Liver function tests
- Electrolytes
- Urinalysis
- Fecal occult blood
- Chest radiography
- Chest, abdominal, and pelvic CT scan (depending on the case)
Study of choice
There is no single diagnostic study of choice for the diagnosis of cancer of unknown primary.
- The algorithm below explains the specific situations where certain diagnostic studies are recommended:[5][4]
| Tumor of unknown primary origin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| • Full medical history and physical exam • Basic blood and biochemical analysis • CT scan of chest, abdomen, and pelvis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Histopathologic examination | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Squamous cell carcinoma | Neuroendocrine carcinoma | Adenocarcinoma and poorly differntiated carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| • Octreoscan • Plasma chromogranin A | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional tests specific to location of metastasis | Additional tests speciifc to gender | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cervical lymphadenopathy | Inguinal lymphadenopathy | Bone metastasis | Men | Women | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| • Panendoscopy • CT scan of head and neck • Diagnostic bilateral tonsillectomy | • Complete clinical examination of external genital organs • Pelvic CT scan or ultrasound | • Anoscopy • Colposcopy (if female) • Complete clinical examination of head and neck • Panendoscopy • Bone scintigraphy • Xrays of painful areas | • PSA • αFP • βHCG | • Mammography • Pelvic ultrasound or CT scan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional tests specific to location of metastasis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Midline and/or mediastinal lymphadenopathy | Cervical and/or supraclavicular lymphadenopathy | Axillary lymphadenopathy | Liver metastasis | Lung metastasis | Bone metastasis | Single metastasis | Pleural effusion | Peritoneal effusion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| • Testicular ultrasound • Chest and abdominal CT scan | • Testicular ultrasound • Head and neck CT scan • Panendoscopy • EBV testing (to rule out undifferentiated nasopharyngeal carcinoma) | Women: • Breast ultrasound • Breast MRI | Women: • αFP assay (if undifferntiated carcinoma) • Colposcopy | Women: • βHCG Men: • Testicular ultrasound • Chest and abdominal CT scan | • Bone scintigraphy • Xrays of painful areas | • Full body CT scan • Bone scintigraphy | • Chest CT scan | Women: • Abdominal and pelvic CT scan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular studies
There is no data to support routine molecular testing for assessment of cancer of unknown primary. In the past, molecular testing was routinely done in an effort to identify the cell or origin.
Diagnostic criteria
There is no single diagnostic study of choice for cancer of unknown primary.
References
- ↑ Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M; et al. (1988). "Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients". Arch Intern Med. 148 (9): 2035–9. PMID 3046543.
- ↑ Briasoulis E, Pavlidis N (1997). "Cancer of Unknown Primary Origin". Oncologist. 2 (3): 142–152. PMID 10388044.
- ↑ Collado Martín R, García Palomo A, de la Cruz Merino L, Borrega García P, Barón Duarte FJ, Spanish Society for Medical Oncology (2014). "Clinical guideline SEOM: cancer of unknown primary site". Clin Transl Oncol. 16 (12): 1091–7. doi:10.1007/s12094-014-1244-0. PMC 4239766. PMID 25392080.
- ↑ 4.0 4.1 Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Laforêt C, Bedossa P, Bertrand G, Coindre JM, Fizazi K (2003). "Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)". Br. J. Cancer. 89 Suppl 1: S59–66. doi:10.1038/sj.bjc.6601085. PMC 2753014. PMID 12915904.
- ↑ Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G; et al. (2015). "Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 26 Suppl 5: v133–8. doi:10.1093/annonc/mdv305. PMID 26314775.